Table 1.

Phases 1 and 2 survey participant characteristics.

Characteristic	Category	Survey 1, n = 301	Survey 2, n = 174
		n (%)	n (%)
Stakeholder typea	Doctor	43 (14.3)	28 (16.1)
	Nurse	19 (6.3)	12 (6.9)
	Pharmacist	6 (2.0)	4 (2.3)
	Stop smoking adviser	48 (16.0)	28 (16.1)
	Other treatment provider	14 (4.7)	12 (6.9)
	Current smoker	14 (4.7)	6 (3.5)
	Ex‐smoker	88 (29.2)	54 (31.0)
	Never smoker	53 (17.6)	33 (19.0)
	Health service commissioner	19 (6.3)	12 (6.9)
	Health‐care guideline developer	9 (3.0)	6 (3.5)
	Researcher	103 (34.2)	61 (35.1)
	Research funder	2 (0.7)	1 (0.6)
	Policymaker	12 (4.0)	8 (4.6)
	Other	73 (24.3)	44 (25.3)
Age (years)	18–30	32 (10.6)	23 (13.2)
	31–40	64 (21.3)	30 (17.2)
	41–50	73 (24.3)	43 (24.7)
	51–60	92 (30.6)	58 (33.3)
	61–70	33 (11.0)	18 (10.3)
	71+	7 (2.3)	2 (1.2)
Gender	Male	130 (43.2)	74 (42.3)
	Female	171 (56.8)	100 (57.7)
Country of residence	Australia	12 (4.0)	8 (4.6)
	Belgium	1 (0.3)	0 (0.0)
	Brazil	2 (0.7)	1 (0.6)
	Canada	14 (4.7)	8 (4.6)
	China	1 (0.3)	0 (0.0)
	Colombia	1 (0.3)	1 (0.6)
	Croatia	2 (0.7)	0 (0.0)
	Denmark	1 (0.3)	1 (0.6)
	Egypt	1 (0.3)	1 (0.6)
	Finland	5 (1.7)	3 (1.7)
	Germany	4 (1.3)	2 (1.2)
	India	7 (2.3)	4 (2.3)
	Ireland	2 (0.7)	2 (1.2)
	Israel	3 (1.0)	3 (1.7)
	Italy	1 (0.3)	0 (0.0)
	Malaysia	1 (0.3)	1 (0.6)
	Netherlands	4 (1.3)	4 (2.3)
	New Zealand	7 (2.3)	3 (1.7)
	Norway	3 (1.0)	2 (1.2)
	Philippines	1 (0.3)	1 (0.6)
	Poland	1 (0.3)	1 (0.6)
	Spain	2 (0.7)	2 (1.2)
	Sweden	3 (1.0)	3 (1.7)
	Switzerland	2 (0.7)	2 (1.2)
	UK	169 (56.2)	90 (51.7)
	USA	49 (16.3)	29 (16.7)
	Uzbekistan	1 (0.3)	1 (0.6)
	Venezuela	1 (0.3)	1 (0.6)

^aMultiple responses permitted.